Enzyme Trading 3% Lower Over Last 7 Days (MLN) : vimarsana.c

StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Rating) in a research report report published on Sunday. The brokerage issued a sell rating on the stock. MBRX has been the subject of a number of other reports. Roth Mkm reaffirmed a buy rating and set a $16.00 price target on shares of […]

Related Keywords

Houston , Texas , United States , Walterv Klemp , Roth Mkm , Renaissance Technologies , Moleculin Biotech Company Profile , Moleculin Biotech Inc , Charles Schwab Investment Management Inc , Moleculin Biotech , Get Rating , Schwab Investment Management , State Street Corp , Street Corp , Waldemar Priebe , Moleculin Biotech Daily , Nasdaq Mbrx , Ambrx , Medical , Initiated Coverage , Stocknews Com ,